Quick Answer
Cyclerion Therapeutics, Inc. reported Cash and Equivalents of $3.24 million for fiscal year 2025.
Cyclerion Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $3.24M | +0.2% |
| 2024 | $3.23M | -57.3% |
| 2023 | $7.57M | -43.4% |
| 2022 | $13.38M | -75.2% |
| 2021 | $53.96M | -0.8% |
| 2020 | $54.40M | -42.7% |
| 2019 | $94.89M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.57M | +59.1% | +52.0% |
| June 30, 2025 | $3.01M | -34.5% | -17.4% |
| March 31, 2025 | $3.64M | -36.1% | +12.6% |
| December 31, 2024 | $3.23M | -57.3% | +12.5% |
| September 30, 2024 | $2.87M | -68.5% | -37.4% |
| June 30, 2024 | $4.59M | -18.7% | -19.5% |
| March 31, 2024 | $5.70M | -20.5% | -24.8% |
| December 31, 2023 | $7.57M | -43.4% | -16.9% |
- Cyclerion Therapeutics, Inc. showed an increase of +0.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Cyclerion Therapeutics, Inc.’s cash and equivalents has declined by 96.6% (from $94.89 million to $3.24 million).
- The most recent figure is from Cyclerion Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: